SCHEMBL29324357

SCHEMBL29324357

CC(=O)c1n[nH]c2cc(F)cc(F)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 1/20 0.35
MAPK1 P28482 2/20 0.35
HCAR2 Q8TDS4 3/20 0.35
MAP2K4 P45985 3/20 0.34
DYRK1A Q13627 5/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPK6 Q16659 1/20 0.33
PRKAB2 O43741 2/20 0.33
PRKAG1 P54619 2/20 0.33
PRKAA2 P54646 2/20 0.33
PRKAA1 Q13131 2/20 0.33
PRKAG3 Q9UGI9 2/20 0.33
PRKAG2 Q9UGJ0 2/20 0.33
PRKAB1 Q9Y478 2/20 0.33
MAPT P10636 1/20 0.33
ALPL P05186 1/20 0.32
CTNNB1 P35222 1/20 0.32
WNT3A P56704 1/20 0.32
WNT1 P04628 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050008 0.85 HCAR2 (0.44) GPR17MAPK1HCAR2MAP2K4MAPK6
SCHEMBL23858844 0.85 HCAR2 (0.44) GPR17MAPK1HCAR2MAP2K4MAPK6
SCHEMBL23872474 0.83 KDM4E (0.48) MAPK1MAP2K4DYRK1APRKAB2PRKAG1
SCHEMBL2955386 0.73 MAP2K4 (0.37) GPR17MAPK1MAP2K4MAPK6ALPL
SCHEMBL8212888 0.73 ADORA2A (0.34) GPR17MAPK1MAP2K4MAPK6
SCHEMBL8205073 0.71 SMN1; SMN2 (0.45) GPR17MAPK1MAP2K4MAPTALPL
SCHEMBL16680979 0.69 MAP4K4 (0.44) DYRK1A
SCHEMBL14738326 0.69 MAP2K4 (0.33) GPR17MAP2K4
SCHEMBL29324202 0.69 SGK1 (0.33) MAP2K4
SCHEMBL1163212 0.69 CHEK1 (0.31) MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP GPR17 1147/4885MAPK1 4226/4885HCAR2 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.